Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.31 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.30 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | CPT1A | P50416 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872296 | 0.97 | — | — | |
| Prolonium SCHEMBL2889745 | 0.81 | MAPT (0.57) | MAPTSLC22A16SMN1; SMN2GALR3BLM | |
| Prolonium SCHEMBL1649967 | 0.77 | MAPT (0.52) | MAPTSLC22A16SMN1; SMN2GALR3BLM | |
| SCHEMBL890513 | 0.75 | — | — | |
| SCHEMBL13380702 | 0.75 | MAPT (0.52) | MAPTSLC22A16SMN1; SMN2GALR3BLM | |
| SCHEMBL10274560 | 0.75 | — | — | |
| Prolonium SCHEMBL11723705 | 0.74 | MAPT (0.50) | MAPTSLC22A16SMN1; SMN2GALR3BLM | |
| Prolonium SCHEMBL1650849 | 0.74 | MAPT (0.50) | MAPTSLC22A16SMN1; SMN2GALR3BLM | |
| Prolonium SCHEMBL5705670 | 0.74 | MAPT (0.50) | MAPTSLC22A16SMN1; SMN2GALR3BLM | |
| Hydrochloric Acid SCHEMBL9819532 | 0.73 | MAPT (0.50) | MAPTSLC22A16SMN1; SMN2GALR3BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024261237-A1 | FLUOROMETHYL-CARNITINE FOR USE AS A CHOLINE TRIMETHYLAMINE (TMA) LYASE INHIBITOR | ALFASIGMA S.P.A. (IT) | 2024-12-26 | — | — | WO | disclosed |
| US-20130202530-A1 | NOVEL RADIOTRACER | IMPERIAL COLLEGE (GB) | 2013-08-08 | — | — | US | disclosed |
| EP-2619170-A2 | ISOTOPIC CARBON CHOLINE ANALOGS | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| EP-2619171-A2 | NOVEL PRECURSOR | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| EP-2619172-A2 | NOVEL RADIOTRACER | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130183239-A1 | ISOTOPIC CARBON CHOLINE ANALOGS | IMPERIAL COLLEGE (GB) | 2013-07-18 | — | — | US | disclosed |
| US-20130178653-A1 | NOVEL PRECURSOR OF RADIOLABELLED CHOLINE ANALOG COMPOUNDS | IMPERIAL COLLEGE (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012040151-A2 | ISOTOPIC CARBON CHOLINE ANALOGS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040133-A2 | NOVEL PRECURSOR | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040138-A2 | NOVEL RADIOTRACER | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178653-A1 | NOVEL PRECURSOR OF RADIOLABELLED CHOLINE ANALOG COMPOUNDS | CHAT, CEPT1, SLC5A7 | CHRM2 33/4885CHRM1 22/4885CHRM3 49/4885 |
| US-20130183239-A1 | ISOTOPIC CARBON CHOLINE ANALOGS | CEPT1, CHAT, CHKB | CHRM2 63/4885CHRM1 54/4885CHRM3 80/4885 |
| US-20130202530-A1 | NOVEL RADIOTRACER | CEPT1, SGMS1, SGMS2 | CHRM2 31/4885CHRM1 14/4885CHRM3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.